Adamas Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 37
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: A5B5CD1D223EN
Leaflet:

Download PDF Leaflet

Adamas Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Adamas Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Adamas Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Adamas Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Adamas Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Adamas Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Adamas Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Adamas Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Adamas Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Adamas Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Adamas Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Adamas Pharmaceuticals, Inc. Snapshot
Adamas Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Adamas Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Adamas Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Adamas Pharmaceuticals, Inc. – Pipeline Products Glance
Adamas Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Adamas Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Adamas Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Adamas Pharmaceuticals, Inc. – Drug Profiles
ADS-5101
  Product Description
  Mechanism of Action
  R&D Progress
ADS-8703
  Product Description
  Mechanism of Action
  R&D Progress
ADS-8902
  Product Description
  Mechanism of Action
  R&D Progress
ADS-8901
  Product Description
  Mechanism of Action
  R&D Progress
Adamas Pharmaceuticals, Inc. – Pipeline Analysis
Adamas Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Adamas Pharmaceuticals, Inc. Pipeline Products By Target
Adamas Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Adamas Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Adamas Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Apr 29, 2010: Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients
Apr 28, 2010: Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy Is Well Tolerated In A Pilot Study Of Immunocompromised Patients With Influenza A
Mar 15, 2010: Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models
Mar 15, 2010: Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models
Nov 19, 2009: Adamas Pharmaceuticals Expands Clinical Study For Triple-Combination Antiviral Drug Therapy (TCAD) In Immune-Compromised Patients
Sep 13, 2009: In Vitro Study Of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy (TCAD)Shows Activity Against Drug-Resistant Influenza Viruses
Sep 13, 2009: In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Sep 03, 2009: Adamas Pharmaceuticals Presents Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
Aug 18, 2009: Adamas Pharmaceuticals Signs CRADA with U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including The Novel H1N1 Pandemic Strain
Financial Deals Landscape
Adamas Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Adamas Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Adamas Pharmaceuticals Secures $40 Million In Series D Financing
Adamas Pharmaceuticals Enters Into Co-Development Agreement With NHRC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Adamas Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Adamas Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Adamas Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Adamas Pharmaceuticals, Inc. – Phase III, 2010
Adamas Pharmaceuticals, Inc. - Phase II, 2010
Adamas Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
Adamas Pharmaceuticals, Inc. - Pipeline By Target, 2010
Adamas Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010
Adamas Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2010
Adamas Pharmaceuticals, Inc., Deals Summary, 2004 to 2010 32

LIST OF FIGURES

Adamas Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Adamas Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Adamas Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Adamas Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
Adamas Pharmaceuticals, Inc. - Pipeline By Target, 2010
Adamas Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010 21

Ask Your Question

Adamas Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: